SOLICITATION NOTICE
A -- Preclinical Medications Discovery and Abuse Liability Testing for NIDA
- Notice Date
- 7/6/2011
- Notice Type
- Presolicitation
- NAICS
- 541712
— Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Institute on Drug Abuse, 6001 Executive Boulevard, Room 4211 - MSC 9559, Bethesda, Maryland, 20892, United States
- ZIP Code
- 20892
- Solicitation Number
- N01DA-12-8904
- Point of Contact
- Pedro M Godinez, Phone: 301.443.6677, Kenneth E Goodling, Phone: (301)443-6677
- E-Mail Address
-
pg186o@nih.gov, kg25d@nih.gov
(pg186o@nih.gov, kg25d@nih.gov)
- Small Business Set-Aside
- N/A
- Description
- The National Institute on Drug Abuse (NIDA) plans to solicit proposals from qualified organizations having in-house capability to perform in vivo rodent and primate pharmacology studies on potential pharmacotherapies for substance use disorders and on new drugs of abuse. This contract will be utilized by the Addiction Treatment Discovery Program (ATDP) within. Data gathered on potential pharmacotherapies will be used by the ATDP and NIDA's Medications Development Program. The data generated on new drugs of abuse will be provided to the DEA by NIDA. Testing shall include but shall not be limited to assessment of the in vivo receptor activity of novel opioid compounds, evaluation of compounds for their ability to produce, block or prevent physical dependence in rodents and/or primates, evaluation of compounds in operant models of behavior, including responding for food reinforcement and intracranial self-stimulation, and evaluation of compounds in other animal models relevant to drug abuse and addiction. The Contractor will be blinded to the identity of proprietary test compounds, and all compounds will be evaluated using protocols as specified by the NIDA Project Officer. Standardized, detailed reports with graphs will be prepared and submitted promptly to the ATDP for each compound tested. It is expected that 10-20 compounds will be evaluated per year in operant behavioral models. The number of compound evaluations in other models will vary significantly from year to year. In order to handle substances under the Controlled Substances Act of 1970, the offerors must indicate possession of current DEA registration for Schedule II-V substances prior to award and apply for Schedule I registration. We anticipate the award of one cost reimbursement contract for a base period of one year, plus four one-year options. The contract will include additional options to cover increased quantities. RFP No. N01DA-12-8904 will be available electronically on or about July 25, 2011. You will access the RFP through the FedBizOpps (URL: http://www.fedbizopps.gov) or through the NIDA website: (URL: http://www.nida.nih.gov/RFP/RFPList.html). All information required for the submission of an offer will be contained in or accessible through the electronic RFP package. Response to the RFP will be due on or about September 15, 2011. NIDA will consider proposals submitted by any responsible offeror. This advertisement does not commit the Government to award a contract. Based upon market research, the Government is not using the policies contained in Part 12, Acquisition of Commercial Items, in its solicitation for the described supplies or services. However, interested persons may identify to the contracting officer their interest and capability to satisfy the Government's requirement with a commercial item within 15 days of this notice.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/NIDA-01/N01DA-12-8904/listing.html)
- Place of Performance
- Address: N/A, United States
- Record
- SN02490077-W 20110708/110706234306-9b556b20277d4c6b2e49c2d3a7f6771f (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |